Skip to content
HealthFree · No signup · 55K/month

CGM Non-Diabetic ROI — Levels / Lingo / Stelo

Behavior-change value vs subscription cost. T2D prevention probability impact. Buy-3-months-then-decide strategy.

  • Instant result
  • Private — nothing saved
  • Works on any device
  • AI insight included
Reviewed by CalcBold EditorialLast verified Methodology

CGM Non-Diabetic ROI Calculator

Drives T2D risk baseline and behavior-change-value horizon. Younger users get longer benefit window.

Drives behavior-change value. Weight-loss highest direct value; biohacking lowest (often diminishes after novelty).

Bumps T2D risk baseline 30% (vs 10% no history). CGM behavior-change has higher prevention value when baseline risk is high.

Below 5.7% = normal. 5.7-6.4% = pre-diabetes. ≥6.5% = diabetes. Pre-diabetes range (5.5-5.7%) maximally benefits from CGM intervention.

Stelo OTC: $89/mo. Lingo: $89/mo. Levels: $199/mo (incl. premium app). Libre 3 (prescription, off-label): $80-120/mo. Most include 2-week sensor + app.

Most insight in first 30-90 days. Levels 'buy-3-months-then-decide' framework holds. Long-term use only if data-acted-upon.

Probability you'll act on CGM data. Most CGM value comes from acting, not collecting. High motivation + meal-tracking discipline = 80+. Low motivation = under 40 (skip CGM entirely).

You might also need

Embed builderDrop the CGM Non-Diabetic on your site →Free widget · 3 sizes · custom theme · auto-resizes · no signupGet embed code

What This Calculator Does

The CGM Non-Diabetic ROI Calculator answers the question the Levels and Lingo marketing pages avoid: at $89-199/month, is wearing a continuous glucose monitor as a non-diabetic actually worth it?The answer depends on three numbers most users don’t honestly assess — the behavior-change value of the data (what’s the dollar value of changing what you eat?), the T2D prevention probability boost (how much does CGM-driven change reduce your decade-out diabetes risk?), and the honest likelihood you’ll act on the data instead of just collecting it.

FDA OTC clearance arrived in March 2024 (Stelo from Dexcom, Lingo from Abbott) — making the device class accessible without a prescription for the first time. The economics flipped at the same moment: the “$89/mo” subscription for a non-diabetic became a real consumer-discretionary line item, not a medical expense. The calculator uses the “buy-3-months- then-decide” framework Levels itself recommends: most insight comes in the first 30-90 days, after which the data repeats known patterns. The output is a net 3-month, 12-month, and lifetime value for your specific case.

The Math / Formula / How It Works

Three primary anchors calibrate the calculator. Levels Health 2023 user research: 78% of users report dietary changes after 30 days; 52% sustain at 6 months. Diabetes Prevention Program: ~58% reduction in T2D progression with intensive lifestyle program; CGM-driven change captures a partial fraction of that effect. ADA 2024 cost-of-T2D data: $13,700/yr direct medical cost compounding to $400-700K lifetime — the prevention value is large if the calculator’s prevention probability is even modest. The willingness-to-act gate is the single biggest swing: a non-diabetic with 80/100 willingness sees full behavior-change value; with 30/100, the device is almost entirely subscription cost.

A worked example. A 35-year-old with no T2D family history, A1C 5.4 (normal), weight-loss as primary goal, paying $89/mo for Stelo, planning 3 months, 60/100 willingness to act. Behavior value = $8,000/yr × 0.60 × 0.25 (3-mo fraction) = $1,200. T2D prevention value modest (no family hx, normal A1C, low baseline risk) ≈ $300. Subscription cost = $267. Net 3-month value = $1,233. Verdict: positive ROI for 3-month trial. Now flip willingness to 25/100 and the same scenario yields net ≈ $33 — and at 12-month duration, net goes deeply negative. The willingness gate is the entire game.

How to Use This Calculator

  1. Get current A1C from your doctor.Below 5.7% = normal; 5.7-6.4% = pre-diabetes (highest CGM benefit window); ≥6.5% = diabetes (insurance covers, this calc doesn’t apply). The pre-diabetes band is where CGM-driven intervention has the largest published prevention effect.
  2. Pick your primary fitness goal. Drives the dollar-value of behavior change: weight-loss highest ($8K/yr), longevity ($6K), metabolic health ($5K), athletic performance ($3K), biohacking ($2K — usually diminishes after novelty).
  3. Note T2D family history. First-degree relative with T2D = +30% baseline lifetime risk = larger prevention-value bonus when behavior change reduces incidence.
  4. Pick your CGM provider and monthly cost.Stelo OTC $89, Lingo OTC $89, Libre 3 prescription $80-120, Levels with full coaching $199. The premium tier is only worth it if you’re using the integrated coaching, not just the glucose data.
  5. Set duration and behavior-change likelihood honestly. Levels framework: 90-day trial. Most insight in first 30-90 days; diminishing returns after. Below 40 willingness = skip CGM entirely; above 70 = extended use justified.

Three Worked Examples

Example 1 — Pre-diabetes A1C 5.9, family history, high willingness

A 42-year-old, A1C 5.9 (pre-diabetes), parent with T2D, weight-loss + metabolic-health goals, Lingo at $89/mo, planning 6 months, 80/100 willingness. Behavior value = $8,000 × 0.80 × 0.5 ≈ $3,200. T2D prevention value (high baseline + family hx + pre-diabetes window) ≈ $2,400. Subscription cost = $534. Net 6-month value = $5,066. Verdict: strongly positive — exactly the user CGM was designed for. The A1C 5.5-5.9 + family hx + high willingness intersection is the highest-ROI population for non-diabetic CGM.

Example 2 — Healthy biohacker, low willingness, 12-month lock

A 28-year-old, A1C 5.2 (very normal), no family hx, biohacking + curiosity goal, Levels at $199/mo, 12-month annual lock, 30/100 willingness (passive data collector). Behavior value = $2,000 × 0.30 = $600. T2D prevention value negligible (low baseline). Subscription cost = $2,388. Net 12-month value = −$1,788. Verdict: do not lock annual. This is the population that accounts for most CGM churn — premium spend without behavior action.

Example 3 — Endurance athlete, 90-day fueling trial

A 38-year-old marathon runner, A1C 5.3, no family hx, athletic performance goal, Stelo at $89/mo, 3-month trial, 70/100 willingness. Behavior value = $3,000 × 0.70 × 0.25 = $525. T2D prevention low. Subscription cost = $267. Net 3-month = $258. Verdict: marginal positive — extend only if data directly improved race fueling. Endurance athletes often see real value from glycogen-depletion timing and recovery-meal sizing; strength athletes typically don’t.

Common Mistakes

  • Inflating willingness-to-act.Most users self-rate willingness 70-80; honest assessment after 30 days is usually 30-50. Track 30 days and ask: did I change a single food choice based on data? Did I change exercise timing? Did I change sleep-meal alignment? If “no” on all three, willingness is below 30.
  • Locking annual on speculative purchases.The Levels “buy-3-months-then-decide” framework is correct. Most insight is in days 1-90; data flattens into known-pattern repetition after. Annual lock at $1,000-2,400 turns a $267 trial into a much bigger commitment than the insight density justifies.
  • Believing accuracy is medical-grade.CGM accuracy (MARD) is ±15-20% — for 100 mg/dL, actual reading is typically 85-115. For non-diabetic use, absolute accuracy matters less than trend pattern (post-meal spike timing, exercise dip). Trend interpretation > absolute readings.
  • Stacking with redundant wearables. If you already wear an Oura, Whoop, or Apple Watch, the marginal insight from CGM may overlap with HRV + recovery + sleep data you already have. Run the wearable-stack ROI calc before adding CGM as a fourth subscription.
  • Ignoring privacy data sharing. Levels + Lingo apps share aggregated data (research opt-in) + advertising. Stelo less invasive. CGM data is biometric health data; opt out of research + analytics during signup if you care.
  • Skipping HSA/FSA reimbursement. If your doctor recommends CGM for prevention (pre-diabetes A1C 5.7-6.4%), it may be HSA/FSA eligible — effective cost drops ~30% via tax-advantaged dollars. Always ask your doctor for a letter of medical necessity before paying cash.

How to Read the Verdict

  1. Net 3-month above $1,000 + willingness above 60 → extend to 6-month or pre-diabetes-management duration. Use the period to lock in 3-5 dietary swaps with measurable A1C/glucose improvement, then graduate off CGM and maintain via lifestyle.
  2. Net 3-month $0-1,000 + willingness 40-60 → do the 3-month trial, do NOT lock annual. Reassess at month 3: did the data drive sustained change? If yes, extend to 6 mo. If no, drop the subscription — the data has been collected; the action is the bottleneck.
  3. Net 3-month negative or willingness below 40 → skip CGM entirely. Behavior change without CGM has higher ROI than CGM data without behavior change. Run the calorie / TDEE calculator and structure a free or low-cost lifestyle program first.
  4. Pre-diabetes A1C 5.7-6.4 + family history → run the calc again with the highest goal value (longevity or weight-loss) — this population sits in the highest-ROI band and may benefit beyond what the standard calc suggests. Discuss with your primary-care physician about formal DPP enrollment before or alongside CGM use.

When CGM Beats Other Health Investments

CGM wins when you’re in the pre-diabetes window (A1C 5.7-6.4%), have family history, and have demonstrated ability to act on data (food log streak, exercise consistency, previous successful behavior change). It loses when you’re a passive data collector or stacking it with multiple existing wearables. For raw body composition and longevity baseline, the biological age calculator and the sleep debt calculator often produce higher-ROI insights at zero subscription cost. If you have actual T2D, the chronic illness lifetime cost calculator is the better starting point — CGM is standard of care there and insurance-covered.

Frequently Asked Questions

The most common questions we get about this calculator — each answer is kept under 60 words so you can scan.

  • FDA OTC clearance — what changed?
    March 2024: FDA cleared Stelo (Dexcom) and Lingo (Abbott) for over-the-counter sale to non-diabetic adults. No prescription required. Made CGM more accessible — same sensor technology as prescription devices. Starting 2024 retail sale via direct-to-consumer + Amazon. Insurance still doesn't cover for non-diabetics.
  • Stelo vs Lingo vs Libre vs Levels?
    Stelo (Dexcom OTC, $89/mo): 15-day sensor, basic app. Lingo (Abbott OTC, $89/mo): 14-day sensor, food-impact insights. Libre 3 (Abbott prescription): 14-day sensor, smaller form, $80-120/mo. Levels ($199/mo): premium app + coaching + integrations + research-backed insights. Choose by ecosystem: Stelo for raw data, Levels for full program.
  • Insurance won't cover CGM for non-diabetics?
    Correct — as of 2025. Insurance covers CGM only for diabetes (T1D, insulin-treated T2D, gestational). Non-diabetic use = self-pay. Some Medicare Advantage plans add for pre-diabetes A1C 5.7-6.4%; verify with plan. HSA/FSA-eligible if doctor-recommended for prevention.
  • Do I need a prescription anymore?
    No for OTC versions (Stelo, Lingo). Yes for prescription Libre 3, Dexcom G7. OTC clearance March 2024 lowered access barrier significantly. Prescription versions sometimes cheaper if insurance covers; OTC convenient for self-pay.
  • What's the short-term insight value?
    Most useful in first 30-90 days. Reveals: hidden glucose spikes from 'healthy' foods (oatmeal, banana, granola), exercise impact on blood sugar, sleep quality correlation, stress glucose response. After ~90 days, insights diminish — most data points repeat known patterns. Levels framework: 2-week-then-decide-to-continue.
  • Athletic performance use?
    Useful for endurance athletes — fuel timing optimization, glycogen depletion prediction, recovery-meal sizing. Less useful for strength/explosive athletes (glycogen-dependent activities benefit; ATP-PCr activities don't). $3-8K/yr behavior-change value depending on competitive level. Most pro endurance athletes use CGM for >12 months.
  • Weight loss correlation?
    Mixed. Levels research: 78% of users report dietary changes after 30 days; correlates with modest weight loss in 6-12 mo follow-up. NOT a direct weight-loss intervention — works through awareness → behavior change. Self-reported impact often over-estimates. Better paired with structured nutrition program than as standalone tool.
  • 2-week vs 90-day program?
    2-week: $89-99 typical, sufficient for initial pattern recognition (foods, exercise, stress). 90-day: $250-400, captures longer patterns (menstrual cycle, sleep variations, vacation impact). Beyond 90 days: diminishing returns. Recommend 2-week trial first; extend to 90 if you're acting on data.
  • How accurate is CGM ± mg/dL?
    Accuracy: ±15-20% MARD (mean absolute relative difference). For 100 mg/dL, actual reading typically 85-115. Calibration via fingerstick can improve. For non-diabetic use, absolute accuracy less important than trend pattern (post-meal spike timing, exercise dip, sleep). Trend interpretation > absolute readings.
  • Privacy data sharing concerns?
    Levels + Lingo apps share aggregated data (research opt-in) + advertising. Stelo less invasive. Personal data handling varies — read each provider's privacy policy. CGM data is health data; HIPAA applies for prescription versions. OTC versions weaker protections. Concerned users should opt out of research + analytics during signup.